MedPath

Budesonide/formoterol maintenance reliever therapy versus fluticasone furoate /vilanterol fixed-dose treatment of asthma on airway inflammation with adult asthma in 4-week treatment;Open-label, randomized, parallel-group comparative study

Not Applicable
Recruiting
Conditions
Bronchial asthma
Registration Number
JPRN-UMIN000017042
Lead Sponsor
Hiroshima Allergy and Respiratory Clinic
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

The patient with the following exclusion criteria is not enrolled 1)Patient with the drug allergy 2)Infection in the absence of effective antimicrobial agents, patients with deep mycosis 3)Patient with tuberculous disease, or respiratory infection 4)Patient with abnormal chest X-ray image 5)Patient with respiratory disease and other respiratory infections in 8 weeks before inclusion 6)Patient is using the beta-blockers, including eye drops or patients with systemic corticosteroids to less than 30 days 7)Patient with serious complications 8)Smoking history of 10 pack years or more and with less than 6 months or by non smoking 9)Patient with pregnancy, or who hope for a pregnancy 10)Patient was deemed inappropriate research attending physician is incorporated into this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The comparison of amount of change in FeNO with NIOXmino between baseline and after 4 weeks treatment
Secondary Outcome Measures
NameTimeMethod
The comparison of the effect in the following background factors after 4week treatment; ACQ score Airway resistance with IOS FEV1.0 Frequency of SABA use
© Copyright 2025. All Rights Reserved by MedPath